Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Metagenomi Inc (MGX)

Metagenomi Inc (MGX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Metagenomi Announces New Appointment to its Board of Directors GlobeNewswire - Wed Jan 15, 7:55AM CST

MGX : 2.84 (+2.90%)
Medicine labratory by gorodenkoff via iStock
2 ‘Monster’ Stocks to Snap Up Before 2025 Barchart - Thu Dec 12, 2024

Analysts at Jefferies have identified Metagenomi and Structure Therapeutics as two "monster" stocks in the biotech sector, with potential gains of up to 1,000%.

GPCR : 26.73 (+5.32%)
MGX : 2.84 (+2.90%)
Metagenomi Presents Highly Specific and Efficient Genome Editing Tools at Nature Conference “RNA at the Bench and Bedside IV” GlobeNewswire - Wed Dec 11, 2024

MGX : 2.84 (+2.90%)
Metagenomi Reports Sustained Factor VIII Activity in Nonhuman Primate Study for Hemophilia A Treatment Candidate MGX-001 Quiver Quantitative, Inc. - Tue Dec 10, 2024

Metagenomi reports sustained Factor VIII activity in NHPs, supporting MGX-001's potential as a hemophilia A treatment.Quiver AI SummaryMetagenomi, Inc. has reported promising results from its ongoing preclinical...

MGX : 2.84 (+2.90%)
Metagenomi Presents Updated Preclinical Data in Hemophilia A at American Society of Hematology (ASH) 66th Annual Meeting GlobeNewswire - Mon Dec 9, 2024

MGX : 2.84 (+2.90%)
Metagenomi: Q3 Earnings Snapshot AP - Wed Nov 13, 2024

Metagenomi: Q3 Earnings Snapshot

MGX : 2.84 (+2.90%)
Metagenomi Reports Business Updates and Third Quarter 2024 Financial Results GlobeNewswire - Wed Nov 13, 2024

MGX : 2.84 (+2.90%)
Metagenomi To Present New Preclinical Hemophilia A Data at American Society of Hematology (ASH) 66th Annual Meeting GlobeNewswire - Tue Nov 5, 2024

MGX : 2.84 (+2.90%)
Metagenomi Presents Novel, Highly Specific and Efficient Adenine Base Editors for Broad Genome Editing at ESGCT GlobeNewswire - Thu Oct 24, 2024

MGX : 2.84 (+2.90%)

Barchart Exclusives

D-Wave’s Largest Investor Is Giving Up on QBTS Stock. Should You? Barchart - 49 minutes ago
According to SEC filings, the Public Sector Pension Investment Board plans to sell all of its QBTS stock holdings. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot